Abera Bioscience AB (NGM:ABERA)

Market Cap	140.62M +36.7%
Revenue (ttm)	9.10M -42.2%
Net Income	-20.99M
EPS	-1.14
Shares Out	20.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,750
Open	6.86
Previous Close	6.76
Day's Range	6.80 - 6.86
52-Week Range	5.15 - 10.05
Beta	0.79
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Abera Bioscience AB

Abera Bioscience AB, a platform and vaccine development company, develops vaccines based on its proprietary and patented platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine. The company also develops projects in Flu, Diarrhea Chlamydia, ETEC, Covid-19, and Tuberculosis. The company was incorporated in 2012 and is hea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 6
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: ABERA

Financial Performance

In 2025, Abera Bioscience AB's revenue was 11.85 million, a decrease of -18.99% compared to the previous year's 14.63 million. Losses were -10.45 million, 850.3% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 9, 2026

Data Sources Report a data error